The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, explains the rationale for and presents the findings of a matching-adjusted indirect comparison (MAIC) that assessed the efficacy of teclistamab versus pomalidomide (pom) plus dexamethasone (dex) for patients with triple-class exposed relapsed/refractory (R/R) multiple myeloma (MM) in England. The findings of this MAIC suggest that, in this patient population, teclistamab elicits superior response rates and a longer time to next treatment (TTNT). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Roche: Honoraria; University College London Hospitals NHS Foundation Trus: Current Employment. Gironella: Janssen: Consultancy, Honoraria; GSK: Consultancy.
